Major Cardiovascular Events Increase in Long-Term Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Therapy: the Tuscany Cost-Effective Study
g the study period (July 2017 to February 2022) 246 patients (mean age 61 ± 11 years, male 73%) who were evolocumab (142/246) or alirocumab (104/246) new users were enrolled in the CERTI...
Our data agree with the large evidence on the effectiveness/tolerability of PCSK9i therapy; however, although PCSK9i represents a good cholesterol-lowering therapeutic option, our study shows a progressive increase in MACEs during the late follow-up that deserve further research.
European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
Source : https://www.sciencedirect.com/science/article/pii/S104366182300292X?via=ihub
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity worldwide. Low-density lipoprotein cholesterol (LDL-C) ...
There is the question of whether combination therapy should be used as the first step to maximise the effectiveness of the pharmacological approach, avoiding the stepwise approach, which is likely to have a detrimental effect on adherence. Given the ever-changing landscape and the availability of new drugs targeting other important lipids,...
Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study
Source : https://www.sciencedirect.com/science/article/pii/S1109966623001537?via=ihub
All content on this site: Copyright © 2023 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies....
This study (HEYMANS) represents the largest multicountry study of PCSK9i use in routine clinical care settings to date. The data from the Greek cohort are in alignment with the full cohort HEYMANS results which demonstrated that expanded use of PCSK9is combined with LLT may increase the likelihood of attaining and maintaining LDL-C goals.
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice
Source : https://www.sciencedirect.com/science/article/abs/pii/S1537189123000307?via=ihub
Despite advances in pharmacotherapy and device innovation, in-stent restenosis (ISR) and stent thrombosis (ST) remain serious complications following ...
Conclusion: Antibody-based PCSK9 inhibition promotes in-stent intimal hyperplasia and blunts vascular healing by increasing VSMC migration, while reducing that of EC. This effect is likely mediated, at least in part, by a differential effect on VSMC and EC senescence. The herein-reported data warrant additional investigations concerning the...
Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy
Source : https://www.sciencedirect.com/science/article/abs/pii/S0735109723064689?via=ihub
The frequency, characteristics and outcomes of patients treated with high-intensity lipid-lowering therapy and showing concomitant atheroma volume red...
Conclusions: Triple regression occurred in one third of AMI patients receiving high-intensity lipid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content and reduced cardiovascular events.